Provided is an immunity enhancing therapeutic vaccine comprising a gene vector based on recombinant adenovirus and three key elements: 1) an HPV antigen including the E6 and E7 multivalent fusion proteins of HPV types 16 and 18 2) an immunologic adjuvant protein fused with said antigen, which protein may be a heat shock protein (HSP) of Mycobacterium tuberculosis 3) an immunostimulant, which may be granulocyte-macrophage colony stimulating factor (GM-CSF). The present vaccine is used for the treatment of human papilloma virus infections and related diseases.
